Suvrat Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 1.51 Cr
- Company Age 18 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 8.50 Cr
- Revenue Growth -9.09%
- Profit Growth -42.86%
- Ebitda -48.66%
- Net Worth 0.31%
- Total Assets 5.59%
About Suvrat Pharmaceuticals
Suvrat Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 March 2006 and has a history of 18 years and 11 months. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 1.51 Cr.
The company has closed loans amounting to ₹8.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pravin Kamalapurkar and Rupali Kamalapurkar serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231MH2006PTC160298
- Company No.
160298
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Mar 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Suvrat Pharmaceuticals?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pravin Kamalapurkar  | Managing Director | 06-Mar-2006 | Current |
| Rupali Kamalapurkar | Managing Director | 06-Mar-2006 | Current |
Board Members
No Directors or KMP associated with company. Upon reviewing the records, we can confirm that there are no Directors or Key Management Personnel (KMP) associated with this company at present.
Financial Performance of Suvrat Pharmaceuticals.
Suvrat Pharmaceuticals Private Limited, for the financial year ended 2018, experienced Minor drop in revenue, with a 9.09% decrease. The company also saw a substantial fall in profitability, with a 42.86% decrease in profit. The company's net worth moved up by a moderate rise of 0.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Suvrat Pharmaceuticals?
In 2018, Suvrat Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹8.50 Cr
Charges Breakdown by Lending Institutions
- State Bank Of Hyderabad : 8.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Dec 2014 | State Bank Of Hyderabad | ₹8.50 Cr | Satisfied |
How Many Employees Work at Suvrat Pharmaceuticals?
Unlock and access historical data on people associated with Suvrat Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Suvrat Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Suvrat Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.